Bronchopulmonary dysplasia (BPD) is an inflammatory lung disorder common in premature infants who undergo mechanical ventilation with supplemental oxygen. Inhaled nitric oxide (iNO) has been used to treat BPD, but clinical outcomes in preterm newborns have been equivocal. Previous studies showed that iNO's effects in alveolar epithelial cells (AEC) are mediated by S-nitrosothiol uptake via L-type amino acid transporter-1 (LAT1). Because LAT1 expression could influence the efficacy of iNO therapy, I sought to determine whether pulmonary LAT1 expression is altered in preterm baboons with experimental BPD and human newborns susceptible to developing BPD. Using fixed lung obtained from 125d and 140d gestation baboons, LAT1 immunostaining was measured in control vs. BPD animals. In adult and gestational controls, LAT1 was strongly expressed in AECs. In 140d BPD lungs, however, LAT1 expression density in alveolar epithelial tissue was significantly decreased. In 125d BPD lungs, LAT1 expression was also significantly diminished in AECs and was instead ectopically localized to interstitial lung regions. The pattern of LAT1 expression in adult human lung was comparable to that observed in adult baboons. LAT1 expression was comparatively diminished in the lungs of premature newborns at autopsy. In human and baboon lung, pulmonary vascular cells expressed LAT1. In summary, LAT1 is expressed in AECs and pulmonary vascular cells in baboons and humans, and BPD pathophysiology decreases pulmonary LAT1 expression and alters its spatial localization. These results could explain the current ineffectiveness of iNO therapy in premature newborns with BPD, as well as guide future work on optimizing NO-based therapies.
Abstract:
Bronchopulmonary dysplasia (BPD) is an inflammatory lung disorder common in premature infants who undergo mechanical ventilation with supplemental oxygen. Inhaled nitric oxide (iNO) has been used to treat BPD, but clinical outcomes in preterm newborns have been equivocal. Previous studies showed that iNO's effects in alveolar epithelial cells (AEC) are mediated by S-nitrosothiol uptake via L-type amino acid transporter-1 (LAT1). Because LAT1 expression could influence the efficacy of iNO therapy, I sought to determine whether pulmonary LAT1 expression is altered in preterm baboons with experimental BPD and human newborns susceptible to developing BPD. Using fixed lung obtained from 125d and 140d gestation baboons, LAT1 immunostaining was measured in control vs. BPD animals. In adult and gestational controls, LAT1 was strongly expressed in AECs. In 140d BPD lungs, however, LAT1 expression density in alveolar epithelial tissue was significantly decreased. In 125d BPD lungs, LAT1 expression was also significantly diminished in AECs and was instead ectopically localized to interstitial lung regions. The pattern of LAT1 expression in adult human lung was comparable to that observed in adult baboons. LAT1 expression was comparatively diminished in the lungs of premature newborns at autopsy. In human and baboon lung, pulmonary vascular cells expressed LAT1. In summary, LAT1 is expressed in AECs and pulmonary vascular cells in baboons and humans, and BPD pathophysiology decreases pulmonary LAT1 expression and alters its spatial localization. These results could explain the current ineffectiveness of iNO therapy in premature newborns with BPD, as well as guide future work on optimizing NO-based therapies.
Introduction:
Bronchopulmonary Dysplasia:
Preterm birth, defined in humans as birth before 37 weeks out of a normal 40-week gestation period, affects approximately one in every ten pregnancies and is caused by a variety of factors ranging from maternal stress to infection (1). The human lung relies on air saccules called alveoli as the sites of gas exchange with the blood (Figure 1 ). However, alveoli do not begin development until late gestation (30 weeks) (2) . As a result, respiratory disorders are the leading cause of preterm newborn deaths (2) . Over the past half-century, the introduction of assisted breathing via mechanical ventilation and oxygen therapy has contributed to marked improvements in survival rates for immature infants, but this trend has come at the price of increased preterm birth complications (3) . In particular, lung injury caused by high-pressure mechanical ventilation has led to the rise of a new disease in preterm infants: bronchopulmonary dysplasia (BPD) (4) . BPD is a chronic disease characterized by sustained inflammation of the lung and is currently the most common morbidity affecting extremely preterm infants born at <29 weeks gestation age (5) . Factors contributing to BPD include fetal and post-natal nutritional deficiencies, oxygen toxicity, and trauma associated with invasive mechanical ventilation (6) .
Current clinical management of BPD involves gentler ventilation, glucocorticoid therapy intended to accelerate fetal lung development, and treatment with exogenous surfactant, a lipidbased film around the air saccules that increases the ability of the lung to expand (5) . Despite these interventions, the incidence of BPD has continued to rise, prompting the need for an improved treatment for the disease.
Inhaled Nitric Oxide Therapy:
Recently, researchers have identified inhaled nitric oxide as a novel candidate therapy for BPD. Nitric oxide gas (NO) is a ubiquitously produced signaling molecule in the body that is known for its ability to widen blood vessels (7) . NO induces this vasodilatory effect by activating the downstream signaling molecule guanylyl cyclase (sGC), which moves calcium into pulmonary vascular smooth muscle cells, resulting in decreased pulmonary vascular resistance.
Furthermore, findings from a substantial body of work in model systems suggest that nitric oxide may enhance lung growth and reduce lung inflammation independently of its effects on blood vessel resistance (8) . As a result, inhaled nitric oxide (iNO) therapy is a widely used treatment for infants with persistent pulmonary hypertension, or abnormally high pressure in the blood vessels of the lung (9, 10) . iNO is also being investigated for clinical application in the treatment of patients with BPD (11).
To date, however, iNO therapy has had equivocal results in preterm infants with pulmonary hypertension and/or BPD, with ineffective outcomes for these conditions in as many as 20% of cases for reasons that are poorly understood (12) . Therefore, the use of iNO on premature infants has recently been discouraged by an NIH consensus panel due to a lack of significant improvement in these patients (8) . Although the results of iNO therapy for treatment of pulmonary hypertension in term and near-term infants have been largely positive, evidence from many clinical trials of iNO treatment in premature infants of ≤34 weeks' gestation age shows inconclusive effects on pulmonary outcomes, survival, and neurodevelopmental outcomes (8) . The factors contributing to the lack of efficacy of iNO therapy in this subgroup are incompletely understood, highlighting the need to better understand the mechanisms behind the pharmacologic effects of NO, as well as how they are affected by disease physiology.
The Role of L-type Amino Acid Transporter-1 in Nitric Oxide Transport:
To explain the heterogeneous outcomes of iNO therapy in clinic, researchers have focused on elucidating the mechanisms behind the transport of iNO into the lung. For years, iNO's pharmacologic effects were attributed to the passage of NO through the cell membrane by simple diffusion. However, recent work has identified the L-type amino acid transporter-1 protein (LAT1) as the major regulator of NO transport across pulmonary alveolar epithelium (13, 14) . In a process termed S-nitrosation, L-cysteine reacts with NO to form S-nitroso-L-cysteine (SNO), which is then transported into pulmonary alveolar epithelial cells through LAT1 ( Figure   2 ) (13) . L-cysteine is shuttled back out of the cell via the x c -amino acid transporter (xCT) (15) .
Multiple lines of evidence indicate that LAT1 is the primary mediator of this NO-derived SNO transport (16, 17) . A previous study in the Auten lab found that mice treated with nebulized Conditions that impair the LAT1 system could theoretically affect iNO efficacy through alterations in SNO uptake in the lung. One such condition is hyperoxia, a preterm management technique that involves administering oxygen at higher fractions than that of atmospheric air (21%) (21) . Supplemental oxygen has been shown to improve the viability of preterm infants, but also increases their risk of chronic lung disease and brain injury (22) . Because patients with BPD receiving iNO therapy are typically premature, they often receive hyperoxia alongside iNO therapy (23) . For these reasons, the Auten lab has tested whether hyperoxia has detrimental effects on nitric oxide transport into the lung. Results showed that hyperoxia (60% or 90%)
impaired NO-derived SNO accumulation in rat and human alveolar epithelial cells (17) . This finding, combined with the knowledge that LAT1 mediates pulmonary SNO transport, suggests that hyperoxia impairs LAT1 function and expression in the lung, potentially limiting SNO transport into the lung. Thus, oxidative stress-induced impairment of the LAT1 system could contribute to the heterogeneous effects of iNO observed in clinical therapy.
Research Goals:
Building on previous research demonstrating the harmful effects of oxidative stress on LAT1 expression, the current study tested the hypothesis that hyperoxia-induced BPD impairs pulmonary LAT1 expression in baboons and humans. On a broader level, this project aimed to translate prior research on LAT1 in mice, rats, and human cell culture to in vivo baboon and human samples, with the objective of determining whether BPD pathophysiology affects LAT1 expression and SNO transport into the lung. To meet this goal, I pursued the following specific aims: 1) to determine the cell-specific expression of LAT1 in healthy human and baboon lung, 2)
to assess LAT1 expression in lungs of baboons with BPD and in human autopsy lung tissue obtained from patients with pathologic diagnoses of extreme prematurity, and 3) to compare the spatial localization and absolute expression of LAT1 between BPD vs. healthy lung samples in both baboons and humans.
Methods
Normal adult and experimental BPD preterm baboon lung were fixed in 4% paraformaldehyde and embedded in paraffin. All baboon lung sections were obtained from the Southwest Foundation for Biomedical Research, San Antonio TX (24) . The 140d and 125d gestation age BPD models were developed by Jacqueline Coalson and colleagues and have previously been described in detail (25) (26) (27) . Adult human donor lung was obtained by pneumonectomy (surgical removal of lung) as previously described (28), and newborn human lungs were obtained at autopsies using a standardized protocol designed to preserve morphologic and molecular integrity, as previously described in detail (29) . Group sizes were between n=3-6 per group. All procedures were approved by the relevant institutional animal care and use committees and institutional review boards.
140d baboon model
In the 140d BPD model, post-delivery, non-BPD control animals (n=4) were placed on positivepressure ventilation and only administered PRN oxygen support for the survival of the animal. 
125d baboon model
In the 125d model, BPD animals were post-natally exposed to PRN oxygen for either 6 days (n=6) or 14 days (n=5) in order to model a moderate and more severe BPD, respectively. In these disease animals, management included antenatal steroids, a single dose of early surfactant replacement, low tidal volume ventilation, and PRN oxygen targeted to achieve P a O 2 55-70 mm Hg as monitored by arterial blood gas measurements (26) . In the control group, 125d GCs (n=4)
were used to assess normal intrauterine development during the time that the BPD animals were undergoing hyperoxic conditions. 125d GCs correspond approximately to human infants at 26 weeks gestation (24) .
Adult human lung
Human lungs were used to determine whether pulmonary LAT1 expression is consistent between baboon and human models. Adult human lung sections were obtained from a clinical lung transplant donor at Duke University Medical Center (28) . In addition, fixed, paraffin-embedded normal lung tissue from two autopsy cases were purchased from a commercial vendor (Amsbio LLC, Cambridge, MA).
Human newborn lung
Human newborn lung sections were obtained from infant autopsy samples at the University of Rochester Medical Center (29) . Preterm human lungs were obtained from infants who were at risk to develop BPD due to respiratory distress syndrome and extreme prematurity, with exposure to either brief or lengthy mechanical ventilatory support. Full-term newborn lungs were obtained from an infant born at 41 weeks gestational age and had no diagnosed lung pathology at the time of death.
Immunohistochemistry Reagents
Tissues were labeled using a mouse monoclonal anti-human LAT1 at a 1:800 dilution (gift of H.
Endou, J Pharma Ltd., Yokohama, Japan). Alveolar type 1 epithelium was identified using rabbit monoclonal anti-human aquaporin 5 (AQP5) at a 1:500 dilution, (Abcam, Cambridge MA, catalog # 92320) and alveolar type II epithelium was identified using rabbit polyclonal antihuman pro-surfactant protein-C (pro-SPC) at a 1:1,000 dilution (Millipore, Temecula CA, catalog # AB3786).
Enzyme detection immunohistochemistry
Paraffin-embedded baboon lung sections obtained from the Southwest National Primate
Research Center were dewaxed, rehydrated through serial gradation of ethanol:water, and subjected to antigen retrieval in 10 mM Tris 1.0 mM EDTA 0.05% Tween™ 20 at pH 9 for 3 minutes using a pressure cooker. Sections were blocked with 5% bovine album serum ( with horseradish peroxidase conjugated to the secondary antibody (Vector). Images were obtained by light microscopy using a digital camera (DP11, Olympus, Center Valley, PA).
Image Analysis
MetaMorph (version 6.1, Molecular Devices, Sunnyvale CA) was used to estimate the expression of LAT1 in stained lung tissue. Ten random non-overlapping high-power fields from each sample per treatment group were imaged at 20x magnification via light microscopy under identical illumination conditions. Each image had a total pixel dimension of 1712 × 1368 pixels.
To perform semi-quantification of LAT1 labeling, a color threshold was set to include only 
Statistical analysis
Grouped data were expressed as mean ± standard error (SE). 
Pulmonary LAT1 expression in 125d baboon model
In contrast to LAT1 expression in the AECs of adult and 140d GC baboons, LAT1 expression in 125d GC, 6d pro re nada (PRN) oxygen, and 14d PRN lungs was most prominent in cuboidal epithelial cells, with diminished apical labeling in cells lining distal air spaces ( Figure 5 ). In the 14d PRN lungs, distal air spaces often lacked cells expressing LAT1. In the 6d PRN and 14d PRN groups, a greater proportion of LAT1 was expressed ectopically in the interstitial regions of the lung, rather than the apical alveolar epithelium as seen in the 125d GC and adult lungs. The proportions of LAT1-positive alveolar lung tissue from all treatment groups of the 125d model were significantly decreased compared to that of the 140d GC baboons ( Figure 6 ). Compared to the 125d GC, the 6d PRN showed a significantly higher proportion of LAT1-positive alveolar lung tissue. The lung tissues of 125d GC, 6d PRN, and 14d PRN animals all exhibited some atelectasis.
Pulmonary LAT1 expression in humans
Normal adult human lung obtained from a donor showed septal and pulmonary vascular endothelial LAT1 labeling ( Figure 7 ) comparable to that seen in adult baboon (Figure 3 ). In full term newborn lung obtained at autopsy from a patient with neuromuscular disease, the LAT1 expression pattern was comparable to that of normal adult human lung (Figure 7 C, D) . In a very premature newborn (27 weeks gestation) that died at 4d of age due to respiratory distress syndrome and sepsis, LAT1 expression was much less prominent in alveolar septal tissue, largely confined to the interstitium, although expression in bronchiolar epithelium was robust.
Qualitative LAT1 expression in the human lung samples (n=6) is summarized in Table 1 .
Discussion
Through this study, I sought to determine if bronchopulmonary dysplasia (BPD) in preterm baboons and humans was associated with impaired LAT1 expression. Because previous studies have shown that nitric oxide (NO) effects depend on S-nitrosothiol (SNO) uptake through L-type amino acid transporter 1 (LAT1), and BPD is a disease condition for which NO treatment has been used, the effects of BPD on LAT1 expression have important clinical implications (17) .
Alveolar LAT1 expression has not been previously reported in primates. I found that the pulmonary LAT1 expression pattern in baboons and humans without lung injury was similar to that which has been previously reported in healthy rodents (13, 17, 30) . In comparison, baboons and humans with lung injury exhibited decreased and ectopic pulmonary LAT1 expression. The current study is the first, to my knowledge, to demonstrate impaired LAT1 under BPD conditions in primate lung.
The effects of experimental BPD on pulmonary LAT1 expression are consistent with a recent report of in vitro hyperoxia effects on alveolar epithelial LAT1 expression (17) . Previous work from the Auten lab demonstrated that hyperoxia impairs SNO uptake, downstream NO effects on soluble guanylyl cyclase activity, and LAT1 function and expression in rat and human alveolar epithelial cell culture (17) . Since oxidative stress was a key component of inducing experimental BPD in the baboon models, I hypothesized that alveolar LAT1 expression would be impaired in the BPD baboons, as was observed.
LAT1 Expression in Human Lungs
While there was prominent LAT1 expression in the alveolar epithelium of all healthy human lungs (n=4), there was markedly diminished alveolar LAT1 expression in 1 of the 2 premature newborns with BPD (n=2) (Figure 7 ). In addition, findings from human LAT1 expression suggest that suppression of LAT1 expression may be temporary because there was low LAT1 expression in very premature newborn lung, but relatively robust expression in specimens obtained at later chronological ages. Any conclusions about the effects of gestation and duration of post-natal intensive care on LAT1 expression must be limited because of the inherent limitations of using autopsy material.
Comparative LAT1 Expression in 125d, 140d, and Adult Baboons
The absolute LAT1 labeling area and the alveolar tissue area of the two groups were compared separately. The 140d gestation age BPD group exhibited lower absolute LAT1 labeling ( Figure 6A ) and greater alveolar tissue area due to a thickening of interstitial tissue secondary to lung injury ( Figure 6B ), both of which contributed to the decrease in normalized LAT1/alveolar tissue ratio.
Adult baboons had significantly higher absolute LAT1 expression and overall alveolar tissue area than any other group ( Figure 6A, B) . However, the higher absolute LAT1 expression was outweighed by a proportionally greater increase in alveolar tissue area, leading to a lower normalized LAT1 expression in adult baboons compared to the 140d GC group ( Figure 6C ). The greater normalized LAT1 expression in the 140d GC group could be due to heightened cell growth and proliferation that occurs during the perinatal period. LAT1 transports large neutral amino acids that are critical carbon and nitrogen sources for the synthesis of proteins, nucleotides, and glutathione. Previous studies have found that LAT1 expression correlates with cell proliferation and angiogenesis (31), thus providing a potential explanation for the observed increase in normalized alveolar LAT1 in 140d GC compared to adult baboons.
Image analysis indicated that baboons with experimental BPD exhibited decreased LAT1 expression specifically in alveolar lung tissue, with a greater proportion of LAT1 in interstitial lung regions ( Figure 6C ). Ectopic expression of LAT1 has been shown to impair LAT1 transport function in a previous study, which found that site-directed mutagenesis of two specific Cys sites in rabbit LAT1 impaired the transporter activity and its expression on the cell membrane (32).
Impaired localization of LAT1 in BPD is also consistent with previous findings in the Auten lab showing diminished membrane LAT1 in hyperoxia-exposed alveolar epithelial cells (17) .
Therefore, alteration of Cys residues in LAT1 could impair folding and transporter insertion into the membrane. Because the induction of experimental BPD was associated with partial displacement of LAT1 expression from the alveolar epithelium, BPD pathophysiology may be associated with protein modifications that impair LAT1 transportation to the membrane, as well as potential effects on LAT1 synthesis.
Clinical Implications
The use of iNO therapy to treat complications of prematurity has increased substantially in recent years, but its use on premature infants has been discouraged by an NIH consensus panel due to a lack of significant improvement in these patients (8) . Although the results of iNO therapy for treatment of pulmonary hypertension in term and near-term infants have been largely positive, evidence from many clinical trials of iNO treatment in premature infants of ≤34 weeks' gestation age shows equivocal and inconclusive effects on pulmonary outcomes, survival, and neurodevelopmental outcomes (8) . The results of the current study showing that LAT1 expression is decreased in the BPD model, combined with the knowledge that NO's pharmacological effects are LAT1-dependent, could explain the heterogeneous effects of inhaled NO used to prevent BPD and to treat other conditions in which high oxygen levels may be used, such as persistent pulmonary hypertension of the newborn.
The effects of LAT1 on SNO transport are likely not solely limited to the lung. LAT1 is also expressed in areas of circulation and other membrane regions where NO transport has been shown to be important, and therefore likely plays an important role in the transport of nitric oxide in these other areas as well. For example, the circulating red blood cell (RBC) is a major SNO reservoir (33) , and previous studies have shown that intravascular delivery of NO results in the transport and delivery of NO as SNOs in the bloodstream (34) . Thus, the results of this study, which seek to clarify the function of LAT1 in SNO transport in vivo, may have important implications for areas outside of the lung that could also benefit from optimized SNO transport.
Finally, while the role of LAT1 is likely important to clinical NO-based therapy, other factors present in infants who develop BPD may also contribute to the overall efficacy of SNO transport in newborns. Oxidation of NO to higher-order nitrogen oxides (i.e. nitrogen dioxide and peroxynitrite) could reduce the amount of NO available for SNO formation or diffusion into the lung (35) . Likewise, oxidative stress could affect the availability of low molecular weight thiols such as cysteine that would be available for SNO formation. Cysteine production and metabolism are impaired in premature infants due to cystathionase deficiency (36, 37) , and treatment conditions may favor oxidation of cysteine to cystine (38) . Therefore, several factors in addition to LAT1 function itself may also contribute to the efficacy of NO therapy in preterm newborns.
Limitations and Future Directions
There are important limitations to these observations. Because of the significant costs inherent to baboon studies, the sample size of each experimental group was small, ranging from n = 3-6 animals per group. In addition, the assessments could only be semi-quantitative and do not measure LAT1 expression on a cell-specific level because of the limitations of immunohistochemistry and the inability to perform whole organ stereological sampling with the archived materials available. Future studies are needed to measure differential LAT1 expression across different cell types in the lung. A: Total LAT1 expression per field is lower in the 140d BPD group compared to the 140d GC group (P = 0.24). Total LAT1 expression was higher in the 125d 6d PRN BPD group than the 125d GC and 125d 14d PRN BPD groups. Adult baboons had significantly greater total LAT1 expression compared to all newborn groups (mean ± SEM, *P < .05 vs. adult).
B:
The average alveolar tissue area is greater in the 140d BPD group compared to the 140d GC group (P = 0.30). There were no significant differences in alveolar tissue area between the 125d groups. The adult group had significantly increased alveolar tissue area compared to all newborn groups (mean ± SEM, *P < .05 vs. adult).
C: Normalized LAT1 = Total LAT1 / Alveolar Tissue Area (ratio of panel A / panel B). The proportion of LAT1-positive alveolar tissue is decreased in the 140d BPD baboons compared to the adult control and 140d GC animals. Adult control animals also exhibited significantly decreased LAT1-positive alveolar tissue compared to 140d GC animals. The proportions of LAT1-positive alveolar tissue in 125d GC, 6d PRN BPD, and 125d 14d PRN BPD showed no significant pair-wise differences, but were all significantly lower than that of the 140d GC animals (mean ± SEM, *P < .01 vs. 140d GC). 
